MedTrace Logo

Exercise Rehabilitation in Patients With Severe Cardiopulmonary Dysfunction on Extracorporeal Life Support

NCT06792617 · Status: ENROLLING_BY_INVITATION · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-01-24

No results posted yet for this study

Summary

Short-term and long-term consequences of severe cardiac and/or lung dysfunction can be increased use of sedation, prolonged bedrest and immobility causing severe loss of muscle mass which could be a risk for muscle weakness, osteoporosis, and lowered endurance. The goal of this study is to show how a structured rehabilitation program can exhibit better short-term and long-term outcomes on patients who are treated with extracorporeal membrane oxygenation (ECMO).

Conditions

  • ExtraCorporeal Membrane Oxygenation (ECMO)
  • Cardiopulmonary Function
  • Rehabilitation

Interventions

OTHER

Mobility (Central or Femoral Cannulation)

Functional Mobility \& ADL's 1. Assisted sitting with progression to unassisted; ADL's 2. Assisted standing with progression to unassisted; ADL's 1. VitalGo bed will be used if unsafe/unable to perform assisted standing. 2. Leg press (VitalGo bed) 3. Ambulation; ADL's

OTHER

Resistance Training

Repetitions will be counted and documented per session per structured exercise.

Sponsors & Collaborators

  • Institute for Extracorporeal Life Support

    lead OTHER

Principal Investigators

  • Linda E Sousse, PhD, MBA · Institute for Extracorporeal Life Support

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-25
Primary Completion
2025-05-31
Completion
2025-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06792617 on ClinicalTrials.gov